PerkinElmer (now Revvity)

Revvity (formerly PerkinElmer) is an American life sciences and diagnostics company focused on pharmaceutical and biotechnology industries, particularly cell therapy and gene therapy developments. Founded in 1937 as PerkinElmer by Richard Perkin and Charles Elmer, the company built its early business in precision optics and transformed over decades through strategic acquisitions and divestitures.

In March 2023, PerkinElmer completed a major corporate split: the Applied, Food and Enterprise Services businesses were sold to private equity firm New Mountain Capital for $2.45 billion (retaining the PerkinElmer name), while the larger life sciences and diagnostics divisions became the publicly-traded company Revvity. The new entity comprises 11,000 of the original 17,000 employees and generated over $3.3 billion in revenue for 2022.

Revvity serves the diagnostics, life sciences, food, and applied markets with nearly 90 years of operating history. The company operates across three strategic areas: Biopharma solutions, Applied Solutions (industrial, environmental, agricultural), and Food Solutions. Headquartered in Waltham, Massachusetts with additional offices in Shelton, Connecticut, Revvity maintains global presence across 35 countries serving customers in 168 countries through direct sales and distributors.

The company's Signals Software division provides cloud-native SaaS platforms for scientific research, including Signals Notebook (ELN used by over 1 million scientists at 4,000 organizations), Signals Medical Review, and ChemDraw. Stock ticker changed from NYSE: PKI to NYSE: RVTY on May 16, 2023 reflecting the transformation to Revvity.

Revvity is pharma-specialized following the 2023 spinoff, with explicit focus on pharmaceutical and biotechnology industries, particularly cell therapy and gene therapy developments. The company's Signals Software division serves over 1 million scientists at 4,000 organizations globally across pharmaceutical, biotech, chemical, agrochemical, flavor and fragrance, and oil & gas R&D sectors.

The company provides pharmaceutical solutions including drug substance and excipient characterisation, drug product assay and dissolution testing, extractables and leachables analysis, elemental impurity testing, medical device testing, stability testing support, and GMP facility support through their OneSource platform. Signals Notebook E3 edition specifically targets pharmaceutical and biotech organisations requiring FDA 21 CFR Part 11 compliance and GxP validation. Specific pharma customer names are undisclosed. The platform offers validation-ready capabilities and holds a SOC 2 attestation.

Revvity generated over $3.3 billion in revenue for 2022 as the life sciences and diagnostics divisions of PerkinElmer. As of November 2025, Revvity's TTM (trailing twelve months) revenue is $3.35 billion USD. The company experienced a 17% revenue decline in its first year post-spinoff, primarily attributed to COVID testing revenue decreases from pandemic-era highs.

The 2023 corporate transformation involved selling the Applied, Food and Enterprise Services businesses to private equity firm New Mountain Capital for $2.45 billion. This strategic divestiture allowed Revvity to focus exclusively on life sciences and diagnostics, particularly pharmaceutical and biotechnology markets. As a publicly-traded company (NYSE: RVTY), Revvity represents the larger segment of the original PerkinElmer, comprising 11,000 employees and the majority of revenue-generating operations.

Revvity's product portfolio spans diagnostics, life sciences research, and scientific software platforms. The Signals Software division provides cloud-native SaaS solutions including Signals Notebook (electronic lab notebook used by 1M+ scientists), Signals Medical Review (clinical trial data management), and ChemDraw (industry-standard chemical drawing tool). The company's flagship ELN platform offers three editions: Individual (free), Professional (team collaboration), and Enhanced Enterprise Edition (E3) for validation-ready GxP environments.

Cloud-native architecture delivers continuous updates every 4-6 weeks (Agile) or three times annually (Deferred, for validated environments). Platform features include native ChemDraw integration, materials management with barcode inventory tracking, real-time global collaboration, Microsoft Office 365 integration, and multi-tenant architecture for phased deployment. Laboratory services and instrumentation through PerkinElmer's legacy operations complement the software offerings with drug characterisation, testing, and GMP facility support capabilities.

Revvity maintains strategic technology partnerships including AWS (Signals Notebook available on AWS Marketplace with cloud deployment), Microsoft (Office 365 integration for collaboration and document management), and ChemDraw technology integration (industry-standard chemical drawing built into Signals platform). The company's global presence across 35 countries with manufacturing facilities in North America, Europe, and APAC enables regional implementation and consulting partnerships.

Integration ecosystem supports REST API connectivity for laboratory systems and enterprise applications. Materials management system includes barcode scanning capabilities for inventory tracking. Professional services are available for implementation assistance, validation support, and training.

Revvity provides professional services including implementation support, validation assistance, and training for Signals Notebook deployments. Global presence across 35 countries serving 168 countries enables regional support coverage, though specific 24/7 support availability and language options are undisclosed.

The E3 edition includes validation documentation to reduce IT burden during GxP implementation. Multi-tenant sandbox environments allow customers to test new features before production deployment. Continuous update model delivers platform enhancements every 4-6 weeks (Agile) or quarterly (Deferred), though user reviews indicate capacity constraints in addressing all customer-requested features from large pharma clients. Free trial and demo options available for platform evaluation.

Revvity traces to PerkinElmer's 1937 founding in precision optics, nearly 90 years of operating history. The company holds SOC 2 Level 1 Attestation for Signals Notebook and Signals Medical Review, granted September 2020. Revvity is publicly traded (NYSE: RVTY) with $3.35 billion TTM revenue.

The Signals Notebook platform has been adopted by over 1 million scientists at 4,000 organisations worldwide. The Signals platform includes ChemDraw integration. No Gartner Magic Quadrant or Forrester Wave recognition is claimed. In 2023, company leadership split PerkinElmer into two entities and rebranded the life sciences division as Revvity.

Revvity publishes product datasheets, validation documentation, and AWS Marketplace listings for the Signals Software platform, which serves 1M+ scientists globally. The 2023 corporate transformation from PerkinElmer to Revvity drew industry press coverage.

Product updates ship every 4-6 weeks on the Agile release cadence. The AWS Marketplace listing provides an additional distribution channel and enterprise procurement pathway. User reviews describe pricing as requiring custom quotes rather than published rates, capacity constraints in addressing large pharma customer enhancement requests, and the platform among "most expensive ELN vendors."